{
  "abstract": "Long-term l-3,4-dihydroxyphenylalanine (l-DOPA) therapy for Parkinson's disease increases plasma concentrations of 3-O-methyldopa (3-OMD), a major metabolite of l-DOPA. This study aimed to investigate the role of 3-OMD in the central nervous system (CNS)-mediated behavioral effects associated with chronic l-DOPA treatment in rats. The effects of 3-OMD on CNS function were examined using two rat models: repeated oral co-administration of l-DOPA/benserazide and single or repeated intraperitoneal (i.p.) administration of 3-OMD. Behavioral assessments included spontaneous locomotor activity, spontaneous alternation behavior (SAB), spatial learning, and depression-like behavior. Plasma and brain concentrations of 3-OMD were also measured. Repeated oral administration of l-DOPA/benserazide maintained plasma 3-OMD concentrations at 1.57-3.50 μg/mL and brain concentrations at 1.68-3.23 μg/g. This treatment reduced SAB by up to 30% and showed a trend toward reduced spatial learning, whereas locomotor activity was unaffected. Repeated i.p. administration of 3-OMD produced comparable plasma and brain concentrations of 3-OMD, reduced SAB, and showed a trend toward reduced spatial learning, without affecting other behaviors. The reduction in SAB was reversed after a 7-d washout period. In contrast, a single administration of 3-OMD had no detectable behavioral effects. In conclusion, sustained, but not transient, exposure to 3-OMD may contribute to reduced working memory performance during chronic l-DOPA therapy.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "name": "Takanori Taogoshi"
    },
    {
      "name": "Kohei Kaneda"
    },
    {
      "name": "Ryohei Kobayashi"
    },
    {
      "name": "Yasuhiro Kimura"
    },
    {
      "name": "Tomoharu Yokooji"
    },
    {
      "name": "Hiroaki Matsuo"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/cbn9s922ab9k6.bib",
  "cited_by": 0,
  "doi": "10.1248/bpb.b26-00358",
  "fulltext_url": "https://www.jstage.jst.go.jp/article/bpb/49/9/49_b26-00358/_article",
  "id": "cbn9s922ab9k6",
  "issns": [
    "1347-5215",
    "0918-6158"
  ],
  "landing_url": "https://www.jstage.jst.go.jp/article/bpb/49/9/49_b26-00358/_article",
  "language": null,
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "jstage-journal",
      "medicine/pharmacology-toxicology"
    ],
    [
      "openalex",
      "2728|Parkinson's Disease Mechanisms and Treatments"
    ]
  ],
  "openalex": "W7212174068",
  "pdf_url": "https://www.jstage.jst.go.jp/article/bpb/49/9/49_b26-00358/_pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-11",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/cbn9s922ab9k6.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:32Z",
      "native_id": "10.1248/bpb.b26-00358",
      "source": "jstage",
      "url": "https://www.jstage.jst.go.jp/article/bpb/49/9/49_b26-00358/_article"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2728|Parkinson's Disease Mechanisms and Treatments",
      "subfield": "neurology"
    }
  ],
  "title": "Pharmacological Role of 3-O-Methyldopa in the Central Nervous System-Mediated Behavioral Effects of L-DOPA in Rats",
  "title_text": "Pharmacological Role of 3-O-Methyldopa in the Central Nervous System-Mediated Behavioral Effects of L-DOPA in Rats",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:32Z",
  "url": "https://research.draconitic.com/paper/cbn9s922ab9k6",
  "venue": "Biological and Pharmaceutical Bulletin",
  "versions": []
}